Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial

A trial with no phase registered on ClinicalTrials.gov. The registry status is recruiting. It plans to enroll 358 participants.

Also called NCT04948749

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; single masking; primary purpose treatment
Phase
Not applicable
Enrolled
  • 358 participants (planned count) (from the registry)
Sponsor
Registry
  • NCT NCT04948749
Started
(actual) (from the registry)
Primary completion
(anticipated) (from the registry)
Completion
(anticipated) (from the registry)
Countries
China (from the registry)
Registry status
  • Recruiting (from the registry)

Technical summary

Registry record NCT04948749. Randomized; single masking; primary purpose treatment. Start 2021-07-02 (actual); primary completion 2027-12 (anticipated). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Drug Eluting Stenting and Aggressive Medical Treatment for Preventing Recurrent Stroke in Intracranial Atherosclerotic Disease Trial
Acronym
DREAM-PRIDE
Condition
ICAD - Intracranial Atherosclerotic Disease
Condition
ICAS - Intracranial Atherosclerosis
Condition
Drug-eluting Stent
Condition
Stroke
Condition
Drug Eluting Stents (DES)
Condition
Medical Treatment
Intervention (Device)
Drug Eluting Stent implantation
Intervention (Drug)
Aggressive medical treatment
Intervention (Behavioral)
Risk factor management
Intervention (Drug)
Standard medical treatment
Lead sponsor
Beijing Tiantan Hospital (class: other)

Record details

Record id
cardio:ct-nct04948749
Content hash
b5af00fbe14e000cc55c86b5acb7add87f8da7a4c20b2bd207c94eee5b8d33d8